All enrolled clients who received no less than a person dose of zosuquidar or placebo throughout induction were monitored for the prevalence of adverse events (439 individuals, 219 on zosuquidar and 210 on placebo). The most common adverse situations ended up relevant to the period of extended and major myelosuppression https://heinrichc443tfr8.bmswiki.com/user